Gene: SLC35A5
Official Full Name: solute carrier family 35 member A5provided by HGNC
Gene Summary: This gene encodes a transmembrane protein which belongs to subfamily 35A of the solute carrier superfamily. The encoded protein is a nucleoside-sugar transporter. Alternative splicing results in multiple transcript variants. [provided by RefSeq, Feb 2017]
Catalog Number | Product Name | Species | Gene | Passage ratio | Mycoplasma testing | Price |
---|---|---|---|---|---|---|
KO14033 | SLC35A5 Knockout cell line (HeLa) | Human | SLC35A5 | 1:3~1:6 | Negative | Online Inquiry |
KO14034 | SLC35A5 Knockout cell line (HCT 116) | Human | SLC35A5 | 1:2~1:4 | Negative | Online Inquiry |
KO14035 | SLC35A5 Knockout cell line (HEK293) | Human | SLC35A5 | 1:3~1:6 | Negative | Online Inquiry |
KO14036 | SLC35A5 Knockout cell line (A549) | Human | SLC35A5 | 1:3~1:4 | Negative | Online Inquiry |
SLC35A5 Gene Knockout Cell Lines are genetically engineered cellular models that specifically lack the SLC35A5 gene, which encodes a nucleotide-sugar transporter involved in the transport of nucleotide sugars across the Golgi membrane. These knockout cell lines serve as a pivotal tool for researchers aiming to dissect the biological roles of SLC35A5 in cellular processes such as glycosylation, cell signaling, and metabolism. By eliminating the expression of SLC35A5, scientists can investigate the resulting phenotypic changes, revealing insights into how aberrations in this pathway may contribute to various diseases, including certain genetic disorders and cancers.
The functionality of the SLC35A5 knockout cell lines is grounded in the principle of gene editing techniques, such as CRISPR-Cas9, which allow for precise alterations of the genome. As a result, researchers can study the impact of SLC35A5 absence on glycan structures, cellular mechanics, and their interactions with the extracellular environment. This is particularly valuable for elucidating the role of glycosylation in cell adhesion and signaling pathways, which are crucial in the context of tumor metastasis and immune responses.
In both research and clinical settings, the SLC35A5 knockout cell lines stand out for their capacity to model diseases linked to glycosylation defects. By providing a platform to test the efficacy of potential therapeutics and to explore molecular mechanisms more thoroughly, these cell lines contribute significantly to the advancement of precision medicine.
Compared to traditional models, these knockout cell lines offer enhanced specificity and relevance, reducing the likelihood of off-target effects and providing more reliable data on the SLC35A5 gene function. They are particularly advantageous for laboratories focusing on cancer research, metabolic diseases, and vaccine development, where understanding glycosylation patterns can lead to breakthroughs in treatment strategies.
Our company specializes in the development and supply of high-quality genetic tools, including these SLC35A5 Gene Knockout Cell Lines, ensuring that researchers are equipped with the resources necessary to accelerate their scientific discoveries and clinical applications. With a commitment to innovation and support, we empower the scientific community to push the boundaries of knowledge.
Please note that all services are for research use only. Not intended for any clinical use.
If your question is not addressed through these resources, you can fill out the online form below and we will answer your question as soon as possible.
There is no product in your cart. |
CD Biosynsis is a leading customer-focused biotechnology company dedicated to providing high-quality products, comprehensive service packages, and tailored solutions to support and facilitate the applications of synthetic biology in a wide range of areas.